Premium
Modulation of Retinoic Acid Receptor Subtypes by 5‐ and 8‐Substituted (Naphthalen‐2‐yl)‐based Arotinoids
Author(s) -
Álvarez Susana,
Lieb Michele,
Martínez Claudio,
Khanwalkar Harshal,
RodríguezBarrios Fátima,
Álvarez Rosana,
Gronemeyer Hinrich,
de Lera Angel R.
Publication year - 2015
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201500150
Subject(s) - transactivation , chemistry , chalcone , benzoic acid , stereochemistry , retinoic acid , retinoid , ligand (biochemistry) , receptor , pharmacology , biochemistry , biology , gene , transcription factor
Retinoid receptors (RARs and RXRs) transduce the signals of their natural and synthetic ligands (retinoids and rexinoids) to cellular transcriptional machinery to induce gene programs that control diverse biological and physiological effects on organisms. All‐ trans ‐retinoic acid, the natural ligand for RARs, is used therapeutically for the treatment of acute promyelocytic leukemia (APL), whereas the synthetic rexinoid bexarotene (a representative member of the aromatic retinoids or arotinoids) is approved for the treatment of cutaneous T‐cell lymphoma (CTCL). Other retinoids have found applications in the topical treatment of skin disorders. In continuation of previous work on the naphthalene‐based arotinoid scaffold, we synthesized a new series of (3‐halo)benzoic acids connected to C5‐ or C8‐substituted naphthyl rings via ( E )‐ethenyl and amide and, for the C5 series, ( E )‐chalcone linkers. These compounds were evaluated as RAR modulators in comparison with previously described dihydronaphthalene arotinoids with the same substitution pattern. Transactivation studies in this series revealed an absence of synergy between small halogen atoms (F, Cl) at C3 and the groups at C5 or C8, as had been observed on some of the dihydronaphthalene analogues. Instead, non‐halogenated 4‐(2‐naphthamido)benzoic acid derivatives transactivated toward the RARβ subtype in preference to the paralogues. The derivatives with bulkier substituents at C8 were characterized as dual RARβ/RARα antagonists, and ( E )‐4‐[(8‐(phenylethynyl)naphthalene‐2‐yl)ethenyl]benzoic acid ( 11 c ), with an ethenyl connector, was shown to be a potent antagonist of RARα.